Takeda logo

Therapeutic Focus - Neuroscience | Takeda Pharmaceuticals

Neuroscience

Doctor and patient

Our focus in neuroscience is driven by the unmet need of patients with neurologic diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these individuals.

Our dedication extends beyond our marketed products and research efforts. We are committed to raising awareness for these conditions, building strategic partnerships with both industry and advocacy, educating patients and physicians, and broadening access to therapies.

Disease areas

  • Rare Epilepsies: Dravet syndrome and Lennox-Gastaut syndrome are two types of rare epilepsies that typically present early in life and are often associated with severe cognitive and developmental impairment in addition to frequent treatment-resistant seizures throughout the person’s lifetime. 1-5 

  • Sleep-wake disorders: Sleep-wake disorders relate to the quality, timing, and amount of sleep that can result in daytime distress and impairment. 6  Narcolepsy type 1 (NT1), narcolepsy type 2, and idiopathic hypersomnia are sleep-wake disorders that are characterized by excessive daytime sleepiness (EDS). 7

  • Parkinson’s disease: A common neurological disorder characterized by slow movement in combination with tremor and/or rigidity. 8,9  The disease is progressive and has a significant impact on patients, families, and caregivers through its degenerative effects on mobility and muscle control. 8,10  In addition, patients may suffer non-motor symptoms such as cognitive changes and sleep disorders. 10

*NOTE: These are not the complete diagnostic criteria and having some or all of these symptoms does not mean you have any one of these diseases. Diagnosis should be based on a complete history and evaluation of the patient. Only a trained health care professional can diagnose these disorders. If you or a loved one is concerned about any of these disorders, please consult your health care professional.

References

  1. Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and Cost-driving Factors in Dravet syndrome Patients and Carers: A prospective, multicenter study from Germany. European Journal of Paediatric Neurology. 2019;23(3):392-403. doi:10.1016/j.ejpn.2019.02.014

  2. Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Dravet Syndrome: An Overview. Cureus. 2019;11:e5006. doi:10.7759/cureus.5006

  3. Dravet C. The core Dravet syndrome phenotype: Core Dravet Syndrome. Epilepsia. 2011;52:3-9. doi:10.1111/j.1528-1167.2011.02994.x

  4. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurology. 2009;8(1):82-93. doi:10.1016/S1474-4422(08)70292-8

  5. Crumrine P. Lennox-Gastaut Syndrome. Journal of Child Neurology. 2001;17:S70-S75.

  6. American Psychiatric Association, American Psychiatric Association, eds. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American Psychiatric Association; 2013.

  7. Sateia MJ. International Classification of Sleep Disorders- Third Edition. Chest. 2014;146:1387–94

  8. Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3

  9. Postuma R, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015;30(12):1591-1601. doi:10.1002/mds.26424

  10. Hiseman JP, Fackrell R. Caregiver Burden and the Nonmotor Symptoms of Parkinson’s Disease. In: International Review of Neurobiology. Vol 133. Elsevier; 2017:479-497. doi:10.1016/bs.irn.2017.05.035